INDICATIONS AND USAGE
Minocycline hydrochloride capsules USP are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms:
Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae
Respiratory tract infections caused by
Mycoplasma pneumoniae
Lymphogranuloma venereum caused by
Chlamydia trachomatis
Psittacosis (Ornithosis) due to
Chlamydia psittaci
Trachoma caused by
Chlamydia trachomatis, although the infectious agent is not always eliminated, as judged by immunofluorescence
Inclusion conjunctivitis caused by
Chlamydia trachomatis
Nongonococcal urethritis, endocervical, or rectal infections in adults caused by
Ureaplasma urealyticum or
Chlamydia trachomatis
Relapsing fever due to
Borrelia recurrentis
Chancroid caused by
Haemophilus ducreyi
Plague due to
Yersinia pestis
Tularemia due to
Francisella tularensis
Cholera caused by
Vibrio cholerae
Campylobacter fetus infections caused by
Campylobacter fetus
Brucellosis due to
Brucella species (in conjunction with streptomycin)
Bartonellosis due to
Bartonella bacilliformis
Granuloma inguinale caused by
Calymmatobacterium granulomatis
Minocycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug:
Escherichia coli
Enterobacter aerogenes
Shigella species
Acinetobacter species
Respiratory tract infections caused by
Haemophilus influenzae
Respiratory tract and urinary tract infections caused by
Klebsiella species
Minocycline hydrochloride capsules USP are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug:
Upper respiratory tract infections caused by
Streptococcus pneumoniae
Skin and skin structure infections caused by
Straphylococcus aureus
(Note: Minocycline is not the drug of choice in the treatment of any type of staphylococcal infection.)
When penicillin is contraindicated, minocycline is an alternative drug in the treatment of the following infections:
Uncomplicated urethritis in men due to
Neisseria gonorrhoeae and for the treatment of other gonococcal infections.
Infections in women caused by
Neisseria gonorrhoeae
Syphilis caused by
Treponema pallidum subspecies
pallidum
Yaws caused by
Treponema pallidum subspecies
pertenue
Listeriosis due to
Listeria monocytogenes
Anthrax due to
Bacillus anthracis
Vincent's infection caused by
Fusobacteruim fusiforme
Actinomycosis caused by
Actinomyces israelii
Infections caused by
Clostridium species
In
acute intestinal amebiasis, minocycline may be a useful adjunct to amebicides.
In severe
acne, minocycline may be useful adjunctive therapy.
Oral minocycline is indicated in the treatment of asymptomatic carriers of
Neisseria
meningitidis to eliminate meningococci from the nasopharynx. In order to preserve the usefulness of minocycline in the treatment of asymptomatic meningococcal carriers, diagnostic laboratory procedures, including serotyping and susceptibility testing, should be performed to establish the carrier state and the correct treatment. It is recommended that the prophylactic use of minocycline be reserved for situations in which the risk of meningococcal meningitis is high.
Oral minocycline is not indicated for the treatment of meningococcal infection.
Although no controlled clinical efficacy studies have been conducted, limited clinical data show that oral minocycline hydrochloride has been used successfully in the treatment of infections caused by
Mycobacterium
marinum.
To reduce the development of drug-resistant bacteria and maintain the effectiveness of minocycline hydrochloride capsules USP and other antibacterial drugs, minocycline hydrochloride capsules USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.